Who
Cynthia Collins
Director
Company insider
Files Form 4 as: Director, MaxCyte; Director, Codexis; Director, Certara; Director, Poseida Therapeutics; Director, DermTech; CEO, Editas Medicine; President & CEO, Genvec; Group Vice President, Beckman Coulter.
In numbers
- Trades disclosed
- 125
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $299K
- Companies
- 8
- Companies where not an officer
- 5
- First trade
- 3 Jan 2008
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —30,421 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —49,579 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —49,579 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —30,421 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —66,350 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —66,350 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT CertaraSoftware | SEC FORM 4 Code M | —15,757 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT Certaraoption or derivative · Software | SEC FORM 4 Code M | —15,757 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT Certaraoption or derivative · Software | SEC FORM 4 Code M | —15,757 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT CertaraSoftware | SEC FORM 4 Code M | —15,757 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —50,790 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —29,210 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | CDXS CodexisChemicals | SEC FORM 4 Code A | —40,983 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | CERT Certaraoption or derivative · Software | SEC FORM 4 Code M | —11,928 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | CERT Certaraoption or derivative · Software | SEC FORM 4 Code A | —15,757 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | CERT CertaraSoftware | SEC FORM 4 Code M | —11,928 at $0.00 | filing |
| 28 Mar 2025filed 1 Apr 2025 | CDXS CodexisChemicals | SEC FORM 4 Code A | —71,174 at $0.00 | filing |
| 8 Jan 2025filed 8 Jan 2025 | Poseida Therapeuticsoption or derivative | SEC FORM 4 Code D | —87,440 at $0.00 | filing |
| 8 Jan 2025filed 8 Jan 2025 | Poseida Therapeuticsoption or derivative | SEC FORM 4 Code D | —28,500 at $0.00 | filing |
| 8 Jan 2025filed 8 Jan 2025 | Poseida Therapeuticsoption or derivative | SEC FORM 4 Code D | —27,350 at $0.00 | filing |
News
Financial Contrast: Alvotech (NASDAQ:ALVO) & Editas Medicine (NASDAQ:EDIT)EDIT · themarketsdaily.com · 18 Oct 2026Editas Medicine (NASDAQ:EDIT) Raised to Overweight at Wells Fargo & CompanyEDIT · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Cynthia Collins; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.